2025-2031 Global Small Nucleic Acid Drug Industry Research & Trends Analysis Report- YH Research

Home > Reports >Pharma & Healthcare > 2025-2031 Global Small Nucleic Acid Drug Industry Research & Trends Analysis Report

2025-2031 Global Small Nucleic Acid Drug Industry Research & Trends Analysis Report

Publication Date: 2025-10-13
Report Id: 2507852
Industry: Pharma & Healthcare
Report Page: 131
Chart: 127

PDF Download

Publication Date: 2025-10-13
Report Id: 2507852
Industry: Pharma & Healthcare
Report Page: 131
Chart: 127

PDF Download

A research report provider that focuses on identifying industry pain points and solving core problems for companies！

Table of Contents
Description
Table of Figures
Need a Quote?

1 Market Overview
1.1 Product Overview and Scope of Small Nucleic Acid Drug
1.2 Global Small Nucleic Acid Drug Market Size and Forecast
1.3 China Small Nucleic Acid Drug Market Size and Forecast
1.4 China Percentage in Global Market
1.4.1 By Revenue, China Small Nucleic Acid Drug Share in Global Market, 2020-2031
1.4.2 Small Nucleic Acid Drug Market Size: China VS Global, 2020-2031
1.5 Small Nucleic Acid Drug Market Dynamics
1.5.1 Small Nucleic Acid Drug Market Drivers
1.5.2 Small Nucleic Acid Drug Market Restraints
1.5.3 Small Nucleic Acid Drug Industry Trends
1.5.4 Small Nucleic Acid Drug Industry Policy

2 Competitive Landscape by Company
2.1 Global Small Nucleic Acid Drug Revenue by Company, 2020-2025
2.2 Global Small Nucleic Acid Drug Participants, Market Position (Tier 1, Tier 2, and Tier 3)
2.3 Global Small Nucleic Acid Drug Concentration Ratio
2.4 Global Small Nucleic Acid Drug Mergers & Acquisitions, Expansion Plans
2.5 Global Small Nucleic Acid Drug Manufacturers Product Type
2.6 Global Geographic Distribution of Small Nucleic Acid Drug Companies

3 China Competitive Situation by Company
3.1 China Small Nucleic Acid Drug Revenue by Company, 2020-2025
3.2 China Small Nucleic Acid Drug Small Nucleic Acid Drug Participants, Market Position (Tier 1, Tier 2, and Tier 3)
3.3 China Small Nucleic Acid Drug Market, Revenue Percentage of Local Players VS Foreign Players (2020-2031)

4 Industry Chain Analysis
4.1 Small Nucleic Acid Drug Industry Chain
4.2 Small Nucleic Acid Drug Upstream Analysis
4.3 Small Nucleic Acid Drug Midstream Analysis
4.4 Small Nucleic Acid Drug Downstream Analysis

5 Sights by Type
5.1 Small Nucleic Acid Drug Classification by Type
5.1.1 Antisense Oligonucleotides (ASO)
5.1.2 siRNA
5.1.3 Other
5.2 by Type, Global Small Nucleic Acid Drug Market Size & CAGR, 2020 VS 2024 VS 2031
5.3 by Type, Global Small Nucleic Acid Drug Market Size, 2020-2031

6 Sights by Application
6.1 Small Nucleic Acid Drug Segment by Application
6.1.1 Neuromuscular Diseases
6.1.2 hATTR
6.1.3 Other
6.2 by Application, Global Small Nucleic Acid Drug Market Size & CAGR, 2020 VS 2024 VS 2031
6.3 by Application, Global Small Nucleic Acid Drug Market Size, 2020-2031

7 Sights by Region
7.1 By Region, Global Small Nucleic Acid Drug Market Size, 2020 VS 2024 VS 2031
7.2 By Region, Global Small Nucleic Acid Drug Market Size, 2020-2031
7.3 North America
7.3.1 North America Small Nucleic Acid Drug Market Size & Forecasts, 2020-2031
7.3.2 By Country, North America Small Nucleic Acid Drug Market Size Market Share
7.4 Europe
7.4.1 Europe Small Nucleic Acid Drug Market Size & Forecasts, 2020-2031
7.4.2 By Country, Europe Small Nucleic Acid Drug Market Size Market Share
7.5 Asia Pacific
7.5.1 Asia Pacific Small Nucleic Acid Drug Market Size & Forecasts, 2020-2031
7.5.2 By Country/Region, Asia Pacific Small Nucleic Acid Drug Market Size Market Share
7.6 South America
7.6.1 South America Small Nucleic Acid Drug Market Size & Forecasts, 2020-2031
7.6.2 By Country, South America Small Nucleic Acid Drug Market Size Market Share
7.7 Middle East & Africa

8 Sights by Country Level
8.1 By Country, Global Small Nucleic Acid Drug Market Size & CAGR，2020 VS 2024 VS 2031
8.2 By Country, Global Small Nucleic Acid Drug Market Size, 2020-2031
8.3 United States
8.3.1 United States Small Nucleic Acid Drug Market Size, 2020-2031
8.3.2 By Company, United States Small Nucleic Acid Drug Revenue Market Share, 2024
8.3.3 by Type, United States Small Nucleic Acid Drug Revenue Market Share, 2024 VS 2031
8.3.4 by Application, United States Small Nucleic Acid Drug Revenue Market Share, 2024 VS 2031
8.4 Europe
8.4.1 Europe Small Nucleic Acid Drug Market Size, 2020-2031
8.4.2 By Company, Europe Small Nucleic Acid Drug Revenue Market Share, 2024
8.4.3 by Type, Europe Small Nucleic Acid Drug Revenue Market Share, 2024 VS 2031
8.4.4 by Application, Europe Small Nucleic Acid Drug Revenue Market Share, 2024 VS 2031
8.5 China
8.5.1 China Small Nucleic Acid Drug Market Size, 2020-2031
8.5.2 By Company, China Small Nucleic Acid Drug Revenue Market Share, 2024
8.5.3 by Type, China Small Nucleic Acid Drug Revenue Market Share, 2024 VS 2031
8.5.4 by Application, China Small Nucleic Acid Drug Revenue Market Share, 2024 VS 2031
8.6 Japan
8.6.1 Japan Small Nucleic Acid Drug Market Size, 2020-2031
8.6.2 By Company, Japan Small Nucleic Acid Drug Revenue Market Share, 2024
8.6.3 by Type, Japan Small Nucleic Acid Drug Revenue Market Share, 2024 VS 2031
8.6.4 by Application, Japan Small Nucleic Acid Drug Revenue Market Share, 2024 VS 2031
8.7 South Korea
8.7.1 South Korea Small Nucleic Acid Drug Market Size, 2020-2031
8.7.2 By Company, South Korea Small Nucleic Acid Drug Revenue Market Share, 2024
8.7.3 by Type, South Korea Small Nucleic Acid Drug Revenue Market Share, 2024 VS 2031
8.7.4 by Application, South Korea Small Nucleic Acid Drug Revenue Market Share, 2024 VS 2031
8.8 Southeast Asia
8.8.1 Southeast Asia Small Nucleic Acid Drug Market Size, 2020-2031
8.8.2 By Company, Southeast Asia Small Nucleic Acid Drug Revenue Market Share, 2024
8.8.3 by Type, Southeast Asia Small Nucleic Acid Drug Revenue Market Share, 2024 VS 2031
8.8.4 by Application, Southeast Asia Small Nucleic Acid Drug Revenue Market Share, 2024 VS 2031
8.9 India
8.9.1 India Small Nucleic Acid Drug Market Size, 2020-2031
8.9.2 By Company, India Small Nucleic Acid Drug Revenue Market Share, 2024
8.9.3 by Type, India Small Nucleic Acid Drug Revenue Market Share, 2024 VS 2031
8.9.4 by Application, India Small Nucleic Acid Drug Revenue Market Share, 2024 VS 2031
8.10 Middle East & Africa
8.10.1 Middle East & Africa Small Nucleic Acid Drug Market Size, 2020-2031
8.10.2 By Company, Middle East & Africa Small Nucleic Acid Drug Revenue Market Share, 2024
8.10.3 by Type, Middle East & Africa Small Nucleic Acid Drug Revenue Market Share, 2024 VS 2031
8.10.4 by Application, Middle East & Africa Small Nucleic Acid Drug Revenue Market Share, 2024 VS 2031

9 Company Profile
9.1 Sarepta Therapeutics
9.1.1 Sarepta Therapeutics Company Information, Head Office, Market Area, and Industry Position
9.1.2 Sarepta Therapeutics Company Profile and Main Business
9.1.3 Sarepta Therapeutics Small Nucleic Acid Drug Models, Specifications, and Application
9.1.4 Sarepta Therapeutics Small Nucleic Acid Drug Revenue and Gross Margin, 2020-2025
9.1.5 Sarepta Therapeutics Recent Developments
9.2 Ionis Pharmaceuticals
9.2.1 Ionis Pharmaceuticals Company Information, Head Office, Market Area, and Industry Position
9.2.2 Ionis Pharmaceuticals Company Profile and Main Business
9.2.3 Ionis Pharmaceuticals Small Nucleic Acid Drug Models, Specifications, and Application
9.2.4 Ionis Pharmaceuticals Small Nucleic Acid Drug Revenue and Gross Margin, 2020-2025
9.2.5 Ionis Pharmaceuticals Recent Developments
9.3 Alnylam
9.3.1 Alnylam Company Information, Head Office, Market Area, and Industry Position
9.3.2 Alnylam Company Profile and Main Business
9.3.3 Alnylam Small Nucleic Acid Drug Models, Specifications, and Application
9.3.4 Alnylam Small Nucleic Acid Drug Revenue and Gross Margin, 2020-2025
9.3.5 Alnylam Recent Developments
9.4 Biogen
9.4.1 Biogen Company Information, Head Office, Market Area, and Industry Position
9.4.2 Biogen Company Profile and Main Business
9.4.3 Biogen Small Nucleic Acid Drug Models, Specifications, and Application
9.4.4 Biogen Small Nucleic Acid Drug Revenue and Gross Margin, 2020-2025
9.4.5 Biogen Recent Developments
9.5 Nippon Shinyaku
9.5.1 Nippon Shinyaku Company Information, Head Office, Market Area, and Industry Position
9.5.2 Nippon Shinyaku Company Profile and Main Business
9.5.3 Nippon Shinyaku Small Nucleic Acid Drug Models, Specifications, and Application
9.5.4 Nippon Shinyaku Small Nucleic Acid Drug Revenue and Gross Margin, 2020-2025
9.5.5 Nippon Shinyaku Recent Developments
9.6 Sobi
9.6.1 Sobi Company Information, Head Office, Market Area, and Industry Position
9.6.2 Sobi Company Profile and Main Business
9.6.3 Sobi Small Nucleic Acid Drug Models, Specifications, and Application
9.6.4 Sobi Small Nucleic Acid Drug Revenue and Gross Margin, 2020-2025
9.6.5 Sobi Recent Developments
9.7 Novartis
9.7.1 Novartis Company Information, Head Office, Market Area, and Industry Position
9.7.2 Novartis Company Profile and Main Business
9.7.3 Novartis Small Nucleic Acid Drug Models, Specifications, and Application
9.7.4 Novartis Small Nucleic Acid Drug Revenue and Gross Margin, 2020-2025
9.7.5 Novartis Recent Developments
9.8 Jazz Pharmaceuticals
9.8.1 Jazz Pharmaceuticals Company Information, Head Office, Market Area, and Industry Position
9.8.2 Jazz Pharmaceuticals Company Profile and Main Business
9.8.3 Jazz Pharmaceuticals Small Nucleic Acid Drug Models, Specifications, and Application
9.8.4 Jazz Pharmaceuticals Small Nucleic Acid Drug Revenue and Gross Margin, 2020-2025
9.8.5 Jazz Pharmaceuticals Recent Developments
9.9 AstraZeneca
9.9.1 AstraZeneca Company Information, Head Office, Market Area, and Industry Position
9.9.2 AstraZeneca Company Profile and Main Business
9.9.3 AstraZeneca Small Nucleic Acid Drug Models, Specifications, and Application
9.9.4 AstraZeneca Small Nucleic Acid Drug Revenue and Gross Margin, 2020-2025
9.9.5 AstraZeneca Recent Developments
9.10 Novo Nordisk
9.10.1 Novo Nordisk Company Information, Head Office, Market Area, and Industry Position
9.10.2 Novo Nordisk Company Profile and Main Business
9.10.3 Novo Nordisk Small Nucleic Acid Drug Models, Specifications, and Application
9.10.4 Novo Nordisk Small Nucleic Acid Drug Revenue and Gross Margin, 2020-2025
9.10.5 Novo Nordisk Recent Developments
9.11 Astellas Pharma
9.11.1 Astellas Pharma Company Information, Head Office, Market Area, and Industry Position
9.11.2 Astellas Pharma Company Profile and Main Business
9.11.3 Astellas Pharma Small Nucleic Acid Drug Models, Specifications, and Application
9.11.4 Astellas Pharma Small Nucleic Acid Drug Revenue and Gross Margin, 2020-2025
9.11.5 Astellas Pharma Recent Developments
9.12 Geron Corporation
9.12.1 Geron Corporation Company Information, Head Office, Market Area, and Industry Position
9.12.2 Geron Corporation Company Profile and Main Business
9.12.3 Geron Corporation Small Nucleic Acid Drug Models, Specifications, and Application
9.12.4 Geron Corporation Small Nucleic Acid Drug Revenue and Gross Margin, 2020-2025
9.12.5 Geron Corporation Recent Developments

10 Conclusion

11 Appendix
11.1 Research Methodology
11.2 Data Source
11.2.1 Secondary Sources
11.2.2 Primary Sources
11.3 Market Estimation Model
11.4 Disclaimer

According to YH Research, the global market for Small Nucleic Acid Drug should grow from US$ 6464 million in 2024 to US$ 19679 million by 2031, with a CAGR of 16.8% for the period of 2025-2031.

Small nucleic acid drugs, such as siRNA, ASO, miRNA, Aptamer, etc., function based on the RNAi process and offer various advantages, including unlimited target drug ability, high specificity, long half-life, faster and more efficient design, development and production process.

Small Nucleic Acid Drug

According to YH Research, the global market for Small Nucleic Acid Drug should grow from US$ 6464 million in 2024 to US$ 19679 million by 2031, with a CAGR of 16.8% for the period of 2025-2031.

Unit: US$ M

www.yhresearch.com

In-depth insight into market trends

Small nucleic acid drugs, composed of nucleotides, represent a novel class of pharmaceuticals that differ significantly from conventional small molecule and antibody-based therapeutics. These agents function by selectively targeting specific genes or their corresponding messenger RNAs (mRNAs), further modulating gene expression and regulating translation-related processes. Prominent examples within this category include antisense oligonucleotides (ASO), small interfering RNAs (siRNAs), microRNAs (miRNAs), and aptamers. The average gross profit margin of this product is 85%.

The Small Nucleic Acid Drug Market is driven by the transformative potential of small nucleic acids, including microRNA, aptamers, and small interfering RNA (siRNA), in treating a wide spectrum of diseases, from genetic disorders to cancer and viral infections. These therapies harness the power of small nucleic acids to modulate gene expression, inhibit specific targets, and diagnose diseases, offering a precise and personalized approach to treatment. As genomics and RNA-based research advance, and precision medicine gains prominence, the demand for small nucleic acid drugs continues to surge. Innovations in nucleic acid design, delivery systems, and gene-editing technologies further contribute to market expansion. Nevertheless, a significant challenge for this market is the need to overcome hurdles related to safe and efficient drug delivery, minimize off-target effects, ensure long-term safety and efficacy, and navigate complex regulatory pathways. Addressing delivery challenges, optimizing pharmacokinetics, and managing development costs are ongoing hurdles. Additionally, the market faces competition from traditional therapeutic approaches, necessitating continuous research and development efforts to unlock the full therapeutic potential of small nucleic acid drugs. Striking a balance between providing safe, effective, and accessible small nucleic acid therapies while addressing scientific and regulatory challenges is paramount for the continued growth of the Small Nucleic Acid Drug Market.

A key trend in the small nucleic acid drugs market is the development of advanced delivery systems to improve the stability and cellular uptake of these therapies. Lipid nanoparticles (LNPs), polymer-based carriers, and exosome-based delivery platforms are gaining traction due to their ability to protect nucleic acids from degradation and enhance target specificity. These innovations are crucial for overcoming the delivery challenges associated with small nucleic acid drugs, particularly for therapies targeting difficult-to-reach tissues such as the brain or tumors.

While small nucleic acid drugs initially focused on rare genetic disorders, there is a growing trend toward applying these therapies to more common diseases, such as cardiovascular conditions, autoimmune disorders, and metabolic diseases. This shift is driven by advancements in gene-editing tools and RNA interference technology, which expand the potential therapeutic targets. The broadening scope of indications is expected to significantly increase the market size and attract more pharmaceutical companies into this space.

This report aims to provide a comprehensive study of the global market for Small Nucleic Acid Drug. Report Highlights:
(1) Global Small Nucleic Acid Drug market size (value), history data from 2020-2024, and forecast data from 2025 to 2031.

(2) Global Small Nucleic Acid Drug market competitive situation, revenue, and market share, from 2020 to 2024.

(3) China Small Nucleic Acid Drug market competitive situation, revenue, and market share, from 2020 to 2024.

(4) Global Small Nucleic Acid Drug segment by region (or country), key regions cover the United States, Europe, China, Japan, South Korea, Southeast Asia, and India, etc.

(5) Global Small Nucleic Acid Drug segment by Type, and by Application, and regional segment by Type, and by Application.

(6) Small Nucleic Acid Drug industry supply chain, upstream, midstream, and downstream analysis.

Market segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia, and Rest of Asia-Pacific)
South America (Brazil, Rest of South America)
Middle East & Africa
Market segment by Type, covers
Antisense Oligonucleotides (ASO)
siRNA
Other

Market segment by Application, can be divided into
Neuromuscular Diseases
hATTR
Other

Market segment by players, this report covers
Sarepta Therapeutics
Ionis Pharmaceuticals
Alnylam
Biogen
Nippon Shinyaku
Sobi
Novartis
Jazz Pharmaceuticals
AstraZeneca
Novo Nordisk
Astellas Pharma
Geron Corporation